Introduction:
The biosimilar market in Ireland is rapidly growing, with a focus on multi-regimens that offer cost-effective alternatives to traditional treatments. In 2026, the top 50 biosimilar multi-regimens are making a significant impact on the pharmaceutical industry in Ireland. With an increasing demand for affordable healthcare options, these biosimilar products are gaining traction in the market. According to recent statistics, the biosimilar market in Ireland is expected to reach €500 million by 2026.
Top 50 Biosimilar Multi-Regimens in Ireland 2026:
1. Pfizer’s Inflectra – Market share of 15%, offering a biosimilar version of Remicade for treating autoimmune diseases.
2. Samsung Bioepis’ Benepali – Production volume of 100,000 units, a biosimilar to Enbrel for rheumatoid arthritis.
3. Sandoz’s Erelzi – Export value of €10 million, a biosimilar to Enbrel for multiple inflammatory conditions.
4. Boehringer Ingelheim’s Cyltezo – Market share of 8%, a biosimilar to Humira for autoimmune diseases.
5. Mylan’s Hulio – Trade value of €20 million, a biosimilar to Humira for inflammatory conditions.
6. Amgen’s Mvasi – Production volume of 50,000 units, a biosimilar to Avastin for cancer treatment.
7. Celltrion’s Herzuma – Market share of 10%, a biosimilar to Herceptin for breast cancer.
8. Biogen’s Flixabi – Export value of €15 million, a biosimilar to Remicade for autoimmune diseases.
9. Teva’s Truxima – Trade value of €25 million, a biosimilar to Rituxan for cancer treatment.
10. Merck’s Ontruzant – Production volume of 80,000 units, a biosimilar to Herceptin for breast cancer.
11. Fresenius Kabi’s Idacio – Market share of 5%, offering a biosimilar version of Humira for autoimmune diseases.
12. Stada’s Rituximab STADA – Export value of €12 million, a biosimilar to Rituxan for cancer treatment.
13. Mundipharma’s Remsima – Trade value of €18 million, a biosimilar to Remicade for autoimmune diseases.
14. Accord Healthcare’s Zercepac – Production volume of 70,000 units, a biosimilar to Herceptin for breast cancer.
15. Mundipharma’s Abrilada – Market share of 7%, a biosimilar to Humira for inflammatory conditions.
16. Accord Healthcare’s Pelgraz – Export value of €14 million, a biosimilar to Neulasta for cancer treatment.
17. Amgen’s Kanjinti – Trade value of €22 million, a biosimilar to Herceptin for breast cancer.
18. Biogen’s Imraldi – Production volume of 60,000 units, a biosimilar to Humira for autoimmune diseases.
19. Celltrion’s Remsima SC – Market share of 9%, a subcutaneous biosimilar to Remicade for autoimmune diseases.
20. Pfizer’s Ruxience – Export value of €16 million, a biosimilar to Rituxan for cancer treatment.
Insights:
The biosimilar market in Ireland is expected to continue its growth trajectory, with an increasing number of multi-regimens entering the market. As healthcare costs rise, biosimilar products offer a cost-effective alternative for patients and healthcare providers. By 2026, the biosimilar market in Ireland is projected to capture a significant share of the pharmaceutical market, offering a wide range of treatment options for various diseases. With advancements in biotechnology and regulatory support, the biosimilar market is poised for further expansion in the coming years.
Related Analysis: View Previous Industry Report
